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Background: Recent studies have reported a human papillomavirus (HPV) prevalence of 20% to 30% in laryngeal squa-
mous cell carcinoma (LSCC), although clinical data on HPV involvement remain largely inconsistent, ascribed by some to dif-
ferences in HPV detection methods or in geographic origin of the studies.
Objective: To perform a systematic review and formal meta-analysis of the literature reporting on HPV detection in
LSCC.
Methods: Literature was searched from January 1964 until March 2015. The effect size was calculated as event rates
(95% confidence interval [CI]), with homogeneity testing using Cochran’s Q and I2 statistics. Meta-regression was used to test
the impact of study-level covariates (HPV detection method, geographic origin) on effect size. Potential publication bias was
estimated using funnel plot symmetry.
Results: One hundred seventy nine studies were eligible, comprising a sample size of 7,347 LSCCs from different geo-
graphic regions. Altogether, 1,830 (25%) cases tested HPV-positive considering all methods, with effect size of 0.269 (95% CI:
0.242 to 0.297; random-effects model). In meta-analysis stratified by the 1) HPV detection technique and 2) geographic study
origin, the between-study heterogeneity was significant only for geographic origin (P 5 .0001). In meta-regression, the HPV
detection method (P 5 .876) or geographic origin (P 5 .234) were not significant study-level covariates. Some evidence for
publication bias was found only for studies from North America and those using non–polymerase chain reaction methods,
with a marginal effect on adjusted point estimates for both.
Conclusions: Variability in HPV detection rates in LSCC is explained by geographic origin of study but not by HPV detec-
tion method. However, they were not significant study-level covariates in formal meta-regression.
Key Words: Laryngeal cancer, papillomavirus, meta-analysis, meta-regression, study heterogeneity, publication bias,
detection method, geographic region.
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INTRODUCTION
The causal relationship between high-risk human
papillomavirus (HPV) infection and head and neck squa-
mous cell carcinoma (HNSCC) is well established, follow-
ing the reports of Syrj€anen and coworkers, who first
suggested this association more than 3 decades ago.1
Since then, several epidemiologic and biological studies
have implicated HPV infection, mainly the HPV 16 geno-
type, as a potential etiological factor for the development
of tumors in the upper aerodigestive tract, especially in
the oropharynx.2–6 Conversely, the role of high-risk HPV
infection in nonoropharyngeal HNSCC is still under dis-
cussion, despite an ever-increasing volume of studies
and meta-analyses published during the past decades.
The majority of HPV-related squamous cell carcino-
mas (SCC) arise in the oropharynx (i.e., tonsils and base
of the tongue), where the reticulated lymphoepithelium
is susceptible to HPV infection–associated oncogenesis.7
Current literature reports an HPV prevalence greater
than 50% in tonsillar carcinomas,2 and recent studies,
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particularly those in the United States, show that up to
80% of oropharyngeal SCCs are HPV related.8 However,
only some 40% of these tumors are transcriptionally
active with HPV 16 E6 and E7 expression.8 Conversely,
even though high-risk HPV can be found in a minority
of SCCs from nonoropharyngeal sites (e.g., oral cavity,
hypopharynx, nasopharynx, and larynx), using a rigor-
ous definition, the truly transcriptionally active HPV
rates are generally low for oral cavity and larynx can-
cer—16.3% and 8.6%, respectively.9
Laryngeal squamous cell carcinoma (LSCC) repre-
sents the second most common malignancy of the head
and neck worldwide,10,11 with 151,000 incidence cases
diagnosed worldwide in 2008.12 Traditionally, LSCC is
ascribed to tobacco and alcohol exposure. However,
molecular evidence has linked HPV, particularly HPV-
16, in the pathogenesis of LSCC.6 Recent meta-analyses
have reported HPV prevalence of 20% to 30% for
LSCC.5,13–15 However, the mere presence of HPV DNA
in a tumor does not necessarily indicate that the virus is
driving or contributing to tumor development or progres-
sion.16 Methods detecting transcriptionally active HPV,
including CDKN2A (p16) immunohistochemistry, quanti-
tative polymerase chain reaction (PCR) or in situ hybrid-
ization for HPV DNA or E6/E7 mRNA, might be
necessary to demonstrate a biologically active virus.16–18
The HPV detection rate among LSCC samples has
remained highly variable, ranging from 0% to 85%.14,19
Some authors have reported that HPV prevalence in
LSCC can vary geographically and by ethnic
group.3,6,14,20–22 possibly due to genetic diversity or envi-
ronmental and cultural differences.20 Besides geographic
and ethnic differences, the disparity in HPV prevalence
usually seen among studies is due to an inadequate dis-
tinction of patients with LSCC from those with other
cancers of the head and neck region, such as oropharyn-
geal SCC.4 Additionally, differences in sensitivity and
specificity of HPV genotyping methods and diagnostic
criteria,3,23 in addition to the limited spectrum of HPV
types analyzed, as well as differences among HPV, have
contributed to the inconsistent results regarding the
HPV prevalence rate in LSCC.
Herein, a systematic review and formal meta-
analysis was performed on HPV prevalence in LSCC,
covering all reports published until March 2015, without
any restrictions concerning the HPV detection method
and geographic origin of the study. The main objective
was to estimate the overall HPV prevalence in LSCC
and to identify whether inconsistent results among stud-
ies are due to different geographic locations and/or HPV
detection methods.
MATERIALS AND METHODS
Data Abstraction
We identified eligible studies by searching MEDLINE and
reference lists from original articles, book chapters, and reviews
from January 1964 until March 2015. No language limitations
were imposed. The search terms included: papillomavirus, HPV,
larynx, squamous cell, verrucous carcinoma, basaloid squamous
cell, papillary squamous cell, cancer, carcinoma, head and neck
cancer. All publications that appeared in peer-reviewed journals
were eligible, irrespective of HPV detection method. Further-
more, the identified reports had to include exact numbers of
analyzed cases and those testing HPV-positive.
Altogether, 783 abstracts were derived from the database,
covering the years 1964 through 2015. This abstract list was
cross-checked against the other databases (Embase and
Cochrane) to find out whether any potential studies were
missed in MEDLINE. No such case was identified; however,
many of the studies detected in MEDLINE were missing in
these two databases. Thus, the final selection was based on
these 783 abstracts.
For the present meta-analysis, a total of 179 original stud-
ies were determined eligible, fulfilling the above-defined crite-
ria. The vast majority of the ineligible studies surveyed were
case reports, case series, or clinical and/or epidemiological stud-
ies (including treatment reports), without HPV testing, or were
studies on HPV in laryngeal papillomas. The formal meta-
analysis was focused on LSCC only, where the different histo-
logical types: 1) SSC, 2) basaloid squamous cell carcinoma, 3)
verrucous carcinoma, 4) spindle squamous cell carcinoma, and
5) papillary squamous cell carcinoma were treated as subgroups
within the study. In final analyses, all subtypes were combined,
because all represent LSCC variants.
From the summaries and/or body texts of each eligible
study, we extracted the following data: histological types of can-
cer, HPV detection methods, geographic region of the study,
total number of cases analyzed, HPV genotypes analyzed and/or
detected, number testing HPV-positive, percent of HPV positiv-
ity, authors, and publication year (see Supporting Table 1 in the
online version of this article). This list of items represents a
modification of the PRISMA (Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses) statements,24 adopted spe-
cifically for this purpose, where event rates represent the effect
size recorded for each original study.
The authors divided HPV detection methods into two cate-
gories: PCR and non-PCR methods. The non-PCR methods com-
prises the following methods: immunohistochemistry (IHC),
Southern blot hybridization (SB), dot blot hybridization (DB),
filter in situ hybridization (FISH), hybrid capture II (HCII), in
situ hybridization (ISH), non-isotopic in situ hybridization
(NISH), and chromogene in situ hybridization (CISH). When
more than one detection method was used, that particular study
was categorized into the PCR group whenever PCR was
included. In this case, only the PCR results were used in calcu-
lations. According to their geographic location, the studies were
divided into the following groups: North America, Central and
South America, Europe, China, other Asia, and Pacific, Africa/
Middle East, and international (data from several regions).
Statistical Analyses
A specific software Comprehensive Meta Analysis (version
2.2.064; Biostat Inc., Englewood, NJ), was used to perform the
meta-analysis. The software calculates the event rates based on
the events and sample size data. To assess overall heterogeneity
in event rates between the different studies, Cochran’s Q homo-
geneity P value as well as I2 statistics (for percentage of varia-
tion) were used.25 To explore the eventual publication bias,
funnel plots were drawn by plotting the logit event rates by
their precision (1/SE),26 evaluated for asymmetry using the fol-
lowing statistics: 1) Begg and Mazumdar rank correlation,27 2)
Egger’s test of the intercept (regression),28 and 3) Duval and
Tweedie’s “trim and fill” method,29 which imputes the results
that are hypothetically missing due to publication bias.
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To assess the variation in event rates due to the differen-
ces between individual studies, we evaluated the study charac-
teristics using stratified meta-analyses and restricted maximum
likelihood meta-regression. Meta-regression formally compares
these differences in event rates across the selected study-level
covariates and estimates the among-study variance.30 Because
of inherent differences in sensitivity between the different HPV
detection methods (PCR and non-PCR), meta-analyses were per-
formed across these strata. Similarly, to distinguish true study-
specific effects from random variation, all analyses were also
stratified by the geographic regions of their origin, another
potential source for variability in HPV prevalence. These two
study characteristics (detection method and geographic location)
were also tested as study-level covariates in meta-regression.
Sensitivity analysis was performed to assess the influence
of each individual study on the strength and stability of the
meta-analytic results, using the one-by-one study removal and
evaluated by descriptively comparing the magnitude and preci-
sion of the random-effects summary event rates.
RESULTS
Eligible Studies
A total of 179 studies (see Supporting Table 1 in the
online version of this article) were considered eligible for
the present analysis,3,4,9,16,19,31–204 comprising a sample
size of 7,347 LSCCs with 1,830 events (approximately
25% of HPV positivity for all methods). In addition,
some studies on HPV prevalence in recurrent respira-
tory papillomatosis (RRP), juvenile-onset papillomas,
and adult-onset papillomas were included as far as they
included also LSCC cases (metachronous or derived from
RRP). A total of 5,161 samples were analyzed with PCR
including 1,387 events (26.8% HPV positivity), whereas
2,186 samples were examined by non-PCR methods,
with 443 events (20.3% HPV positivity) (Table I). The
methods used to evaluate the HPV involvement include
the following: PCR and non-PCR methods (IHC, DB, SB,
ISH, FISH, NISH, HCII, and CISH). In studies using
more than one technique, PCR results were computed
whenever available3,4,16,19,42,46,48,51,52,54,56–59,61,62,64–69,72,
74–77,79,81–87,91,92,94–98,100,101,103–106,108–111,113–136,138–144,146–149,
151–153,156–163,166–173,175–184,185,187,190,191,195–197,200–202 Con-
versely, when PCR was not used or its results were not
available, the study was included in the non-PCR
method group.9,31–41,43–45,47,49,50,53,55,60,63,70,71,73,78,80,88–90,
93,99,102,107,112,137,145,150,154,155,164,165,174,185,188,189,192–194,198,
199,203,204
Analytical Results
Point estimates of event rates. The crude HPV-
positivity (1,830/7,347) translates to event rates of 0.292
(95% confidence interval [CI] 0.281 to 0.304) using the
fixed-effects (FE) model, and 0.269 (95% CI: 0.242 to
0.297) using the random-effects (RE) model. There is a
significant heterogeneity between the studies using PCR
and non-PCR techniques (Cochran’s Q statistics, P 5
.0001) (Table I). This also applies to overall comparison
within strata (P 5 .0001), but not for between strata (P
5 .985). The percentage of variation (I2) is highest
(79.7%) for non–PCR-based studies. Using the RE
model, both PCR and non-PCR techniques give exactly
the same point estimates of HPV prevalence (0.271,
27.1%).
There is significant heterogeneity between the stud-
ies from different regions (P 5 .0001), with a variation of
68.9% (North America) to 78% (Europe) (Table II). The
highest effect size (39.9%) is found in studies derived
from China, followed by those conducted in Central and
South America (29%) and Europe (27.9%). The between-
strata comparison (RE model) indicates that the hetero-
geneity between the studies from different geographic
regions is statistically significant (P 5 .0001).
Meta-regression. In meta-regression for HPV
methods, the PCR method (n 5 127) resulted in a point
estimate that was significantly different (P 5 .0001)
from the non-PCR methods (n 5 52, reference), even
though the HPV detection method was not a significant
study-level covariate (P 5 .876) in meta-regression
(Table III).
In meta-regression for geographic location, all loca-
tions except Europe (P 5 .023) resulted in point esti-
mates that were significantly different from the
reference (North America). However, in meta-regression,
the geographic origin of the study did not have a signifi-
cant impact on the effect size (P 5 .234) (Table IV).
TABLE I.
Meta-analysis of the 179 Studies on Laryngeal Squamous Cell Carcinoma Stratified by the Human Papillomavirus Detection Method.
HPV Detection
Method
No. of
Studies Events
Sample
Size
Point Estimates of Event
Rates (Fixed-Effects Model)
Point Estimates of Event
Rates (Random-Effects
Model)
Homogeneity
(Cochran’s Q)* I2*
Homogeneity
(P Value)*
Point
Estimate 95% CI
Point
Estimate 95% CI
PCR 127 1,387 5,161 0.311 0.297 to 0.325 0.271 0.241 to 0.302 564.857 77.693 .0001
Non-PCR 52 443 2,186 0.243 0.223 to 0.265 0.271 0.215 to 0.335 256.771 79.748 .0001
Summary 179 1,830 7,347 0.292 0.281 to 0.304 0.269 0.242 to 0.297 846.783 78.861 .0001
Total within (FE) 821.628 .0001
Total between (FE) 25.155 .0001
Total between (RE) 0.0000 .985
*Only calculated for fixed-effects model.
CI 5 confidence interval; FE 5 fixed-effects model; PCR 5 polymerase chain reaction; RE 5 random-effects model.
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Publication bias. There was no evidence for publica-
tion bias among studies based on PCR. For studies using
non-PCR techniques, there was some evidence of publica-
tion bias. Duval and Tweedie’s trim-and-fill method imputed
three hypothetically missing studies, with a seemingly size-
able effect on adjusted point estimates (from 0.201 to 0.316),
but this difference was not statistically significant as tested
by Begg (P5 .138) and Egger’s (P5 .114) tests.
There was no evidence of publication bias among
studies from Central and South America, China, other
Asia and Pacific, and from Europe. For studies from
North America, the Duval and Tweedie’s trim-and-fill
method imputed two hypothetically missing studies,
with a slight effect on adjusted point estimates (from
0.191 to 0.289), which was not statistically significant:
Begg (P 5 .071) and Egger’s (P 5 .134).
Sensitivity analysis. Meta-analytic results seemed
robust to all (n 5 179) one-by-one study removals, with
no change in the magnitude and precision of the FE and
RE summary point estimates of the effect size.
DISCUSSION
This meta-analysis with formal meta-analysis and
meta-regression was performed to assess whether the
wide variation in HPV prevalence in LSCC is due to dif-
ferent detection techniques as reported earlier.3,5,15,23
There is little doubt that a marked heterogeneity exists
between the studies based on PCR and non-PCR meth-
ods using the Q test and I2 index (Table I). This marked
heterogeneity justifies the adoption of the RE model to
analyze the summary statistics.25,205–209 Using the RE
model, the most important conclusion implicates that
there is no true heterogeneity between studies using dif-
ferent HPV detection techniques, as indicated by the
nonsignificant homogeneity P value (P 5 .985) for the
between-study comparison. Thus, we can revisit the con-
cept raised in several studies suggesting that the differ-
ences in HPV prevalence in LSCC would be explained
by different HPV detection techniques (intermethod var-
iations)5 or due to differences in detection criteria in the
same method (intramethod variations).47,210,211
TABLE II.
Meta-analysis of the 179 Studies on Laryngeal Squamous Cell Carcinoma Stratified by Their Geographic Area.
HPV Detection Method
No. of
Studies Events
Sample
Size
Point Estimates of Event
Rates (Fixed-Effects Model)
Point Estimates of Event
Rates (Random-Effects
Model)
Homogeneity
(Cochran’s Q)* I2*
Homogeneity
(P Value)*
Point
Estimate 95% CI
Point
Estimate 95% CI
North America 45 370 1,652 0.236 0.214 to 0.259 0.246 0.201 to 0.298 141.779 68.966 .0001
Central and
South America
14 190 640 0.324 0.286 to 0.364 0.290 0.217 to 0.377 57.424 77.361 .0001
Europe 82 828 3,266 0.308 0.290 to 0.327 0.279 0.238 to 0.323 371.602 78.202 .0001
Other Asia and Pacific 19 131 931 0.178 0.152 to 0.209 0.168 0.116 to 0.237 71.601 74.861 .0001
China 17 307 770 0.415 0.378 to 0.452 0.399 0.323 to 0.479 68.830 75.301 .0001
Africa and ME† 1 1 10
Intercontinental† 1 3 78
Summary 179 1,830 7,347 0.292 0.281 to 0.304 0.269 0.242 to 0.297 846.783 78.861 .0001
Total within (FE) 711.236 .0001
Total between (FE) 135.547 .0001
Total between (RE) 25.2057 .0001
*Only calculated for fixed-effects model.
†Only one study, meta-analysis redundant (omitted from the summary effect analysis).
CI 5 confidence interval; FE 5 fixed effects; RE 5 random effects.
TABLE III.
Effect of HPV Detection Method on the Effect Size in Maximum Likelihood Meta-regression.
Study-Level Covariates
No. of Studies
(Homogeneity P Value)*
Effect Size† Difference in Effect Size Estimates‡
HPV Detection Method
Point
Estimate 95% CI
Difference in
Point Estimates 95% CI P Value
Non-PCR 52 (.0001) 0.271 0.215 to 0.335 1.000 Ref
PCR 127 (.0001) 0.271 0.241 to 0.302 0.065 0.044 to 0.086 .0001
Meta-regression for
both methods
Slope: 0.028 (95% CI: 20.323 to 0.379) (P 5 .876); intercept: 21.044 (95% CI: 21.510 to 20.578) (P < .001)
Slope: effect parameter (5 regression coefficient b1); intercept (5 coefficient b0).
*Cochran’s Q.
†Random-effects model.
‡Calculated using Stata.
CI 5 confidence interval; HPV 5 human papillomavirus; PCR 5 polymerase chain reaction.
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The other study-level covariate was the geographic
origin of the study, also listed as a potential cause of var-
iation in HPV prevalence.6,15,23 To validate this concept,
we performed a meta-analysis stratified by the geo-
graphic area covered by the study (Table II). Both the Q
test and the I2 index demonstrated a marked heteroge-
neity between the studies within all different geographic
areas, irrespective the number of studies included in
each stratum. Both the within-strata and between-strata
comparisons were significant, confirming the substantial
heterogeneity between 1) the studies analyzing LSCC in
the same geographic area and between 2) the studies
assessing LSCC from different geographic areas. In addi-
tion, when the RE model was used to interpret the sum-
mary statistics, a significant (P 5 .0001) homogeneity P
value was obtained for the between-strata comparison.
This implicated that this wide variation (16.8% to
39.9%) in HPV prevalence from different geographic
regions is significant according to the strict meta-
analytical criteria. Table II depicts that the extreme of
variation occurred in geographic areas with intermediate
number of studies, whereas the summary effect size is
within a rather narrow range (24.6%–27.9%) in regions
with larger number of studies such as Europe and North
America, emphasizing the need for meta-regression.
We also performed meta-regression to formally com-
pare these differences in summary effect sizes.29 In
meta-regression with the HPV detection method as the
covariate, the regression coefficient for the effect param-
eter (b1, or slope) was not statistically significant (P 5
.876) (Table III). The same was true when the geo-
graphic area of the study (P 5 .234) (Table IV), was
tested for its impact as a study-level covariate. These
data formally confirmed that HPV detection method and
geographic area of the study are not significant study-
level covariates accounting for the heterogeneity of the
summary effect size estimates in LSCC studies.
Some evidence for publication bias was detected,
but this usually had an insignificant effect on the
adjusted point estimates in the stratified meta-analysis.
Most importantly, there was no evidence on publication
bias among PCR-based studies, and the slight publica-
tion bias among the non–PCR-based studies resulted in
an insignificant change (Begg test, P 5 .138; Egger test,
P 5 .114) of the point estimates (20.1%–31.6%). As to the
geographic areas, some publication bias was evident
only for studies from North America, with a slight
impact on summary point estimates (19.1%–28.9%),
which also proved to be nonsignificant (Begg test, P 5
.071; Egger test, P 5 .134).
One of the potential limitations of the present
meta-analysis is associated with the shortcomings of the
Q statistic, known to have a poor power to detect true
heterogeneity in meta-analysis including a small number
of studies, but excessive power to detect even insignifi-
cant variability when a large number of studies is avail-
able.25,205–209 This can be a potential weakness only
when the meta-analysis is stratified by HPV detection
method and geographic areas of the study, which inevi-
tably leads to strata with limited number of studies.
This, however, is compensated by the I2 index, because
the indices obtained from meta-analyses with different
numbers of studies and different effect metrics are
directly comparable.209
Taken together, this meta-analysis based on 179 eli-
gible studies on HPV detection in LSCC implicates that
HPV prevalence in LSCC was 25%, and it varies accord-
ing to 1) HPV detection method and 2) geographic origin.
However, in stratified meta-analysis, this variability
reaches statistical significance only for geographic area
of the study. In formal meta-regression, however, none of
these study characteristics are significant study-level
covariates accounting for the heterogeneity of HPV prev-
alence. Finally, it is important to note that this study
does not analyze the physical state or transcriptional
activity of HPV in these tumors. Multicentric follow-up
studies are needed to further characterize the role of
HPV in LSCC.
TABLE IV.
Effect of Geographic Origin of the Study on the Effect Size in Maximum Likelihood Meta-regression.
Study-Level Covariates,
Geographic Origin of Study
No. of Studies
(Homogeneity P Value)*
Effect Size† Difference in Effect Size Estimates‡
Point
Estimate 95% CI
Difference in
Point Estimates 95% CI P Value
North America 45 (.0001) 0.246 0.201 to 0.298 1.000 Ref
Central and South America 14 (.0001) 0.290 0.217 to 0.377 0.072 0.032 to 0.113 .0001
Europe 82 (.0001) 0.279 0.238 to 0.323 0.029 0.004 to 0.054 .023
Other Asia and Pacific 19 (.0001) 0.168 0.116 to 0.237 20.083 20.113 to 20.053 .0001
China 17 (.0001) 0.399 0.323 to 0.479 0.175 0.135 to 0.215 .0001
Africa/ME§ 1
Intercontinental§ 1
Meta-regression for all Slope: 0.072 (95% CI: 20.046 to 0.191) (P 5 .234); intercept: 21.191 (95% CI: 21.555 to 20.827) (P < .001)
Slope: effect parameter (5 regression coefficient b1), intercept (5 coefficient b0)
*Cochran’s Q.
†Random-effects model.
‡Calculated using Stata.
§Studies omitted from calculations.
CI 5 confidence interval.
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CONCLUSION
In stratified meta-analysis, variability in HPV
detection rates in LSCC is explained by geographic area
of the studies and not by HPV detection method. None
of the two were significant study-level covariates in for-
mal meta-regression.
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